ReviewThe Canadian journal of cardiology2006
The role of global risk assessment in hypertension therapy.
Review in The Canadian journal of cardiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Guideline
- The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.The Canadian journal of cardiology · 2009Guideline
- The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.The Canadian journal of cardiology · 2007Guideline
- A naturopathic approach to the prevention of cardiovascular disease: cost-effectiveness analysis of a pragmatic multi-worksite randomized clinical trial.Journal of occupational and environmental medicine · 2014Trial
- Calibration and discrimination of the Framingham Risk Score and the Pooled Cohort Equations.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Observational
- Identification of clinically relevant features in hypertensive patients using penalized regression: a case study of cardiovascular events.Medical & biological engineering & computing · 2019Article
- Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients with diabetes: results of the POWER survey.Diabetes, metabolic syndrome and obesity : targets and therapy · 2015Article
- Evolution of lipid management guidelines: evidence might set you free.Canadian family physician Medecin de famille canadien · 2014Review
- New insights into the management of hypertension and cardiovascular risk with Angiotensin receptor blockers: observational studies help us?The open cardiovascular medicine journal · 2014Article
- Effect of eprosartan-based antihypertensive therapy on coronary heart disease risk assessed by Framingham methodology in Canadian patients: results of the POWER survey.Vascular health and risk management · 2014Observational
- The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk.The Canadian journal of cardiology · 2010Review
- Traditional statistical methods for evaluating prediction models are uninformative as to clinical value: towards a decision analytic framework.Seminars in oncology · 2010Review
- Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?The Canadian journal of cardiology · 2008Article
- The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk.The Canadian journal of cardiology · 2008Review
- Adding "value" to clinical practice guidelines.Canadian family physician Medecin de famille canadien · 2007Article
- Comprehensive cardiovascular risk management--what does it mean in practice?Vascular health and risk management · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To maximize the benefits of preventive therapy, lipid and hypertension guidelines increasingly recommend that high-risk individuals be targeted for treatment. An individual's risk of developing cardiovascular disease depends on many risk factors, such as age, sex, blood pressure, blood lipid levels, body weight, physical fitness, smoking habits and familial predisposition. Multivariable statistical models have therefore been developed to better estimate the global risk of future coronary events and stroke. A Canadian model is not currently available because a prospective cohort of sufficient size has not been followed in Canada. Therefore, global risk assessment among Canadians can only be completed using models developed in the United States or Europe. In the present review, cardiovascular risk tools are identified that may be appropriate for Canadians, including those based on the Framingham model, the Cardiovascular Life Expectancy Model, the United Kingdom Prospective Diabetes Study (UKPDS) model and the Systematic COronary Risk Evaluation (SCORE) model. The accuracy of the Framingham model and the Cardiovascular Life Expectancy Model are also evaluated using data from a small, prospective Canadian cohort. Finally, a framework is proposed to assist health care professionals in choosing the global risk tool most appropriate for their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.